EFG Asset Management North America Corp. Sells 9,323 Shares of Natera, Inc. (NASDAQ:NTRA)

EFG Asset Management North America Corp. lessened its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 17.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,051 shares of the medical research company’s stock after selling 9,323 shares during the quarter. Natera makes up 1.0% of EFG Asset Management North America Corp.’s portfolio, making the stock its 16th biggest position. EFG Asset Management North America Corp.’s holdings in Natera were worth $6,975,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Blue Trust Inc. raised its holdings in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc raised its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. boosted its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after acquiring an additional 332 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the company’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now owns 267,629 shares in the company, valued at approximately $44,150,756.13. This represents a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 24,861 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $4,101,319.17. Following the completion of the transaction, the insider now directly owns 140,684 shares in the company, valued at approximately $23,208,639.48. This represents a 15.02 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 306,797 shares of company stock worth $48,940,883. Insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Sanford C. Bernstein raised their target price on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Piper Sandler raised their price objective on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Tuesday, March 4th. Barclays initiated coverage on shares of Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 target price on the stock. JPMorgan Chase & Co. lifted their price target on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, Natera presently has an average rating of “Moderate Buy” and a consensus price target of $178.12.

Natera Trading Up 1.8 %

Natera stock opened at $153.83 on Tuesday. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The business’s fifty day moving average is $160.92 and its 200 day moving average is $150.26. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The stock has a market capitalization of $20.80 billion, a PE ratio of -87.40 and a beta of 1.80.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.